Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plasma exchange in COVID-19 patients with invasive mechanical ventilation
NCT04374539Phase 2Terminated
- Sponsor
- Fundació Clínic per a la Recerca Biomèdica
- Start
- Apr 2020
- Primary completion
- Jun 2021
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of High-Volume Plasma Exchange + GCSF in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Fundació Clínic per a la Recerca Biomèdica. Primary endpoint: All-cause mortality at 28 days. Started Apr 2020; status: terminated.
02
Drugs
High-Volume Plasma Exchange + GCSF
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04374539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04374539.